Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 pridopidine study in Huntington's disease
NL-OMON61722Phase 3Not yet recruiting
- Sponsor
- Ferrer
- Start
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of pridopidine in Huntington disease (HD), sponsored by Ferrer. Primary endpoint: Change from baseline to Week 52 in cUHDRS. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
pridopidine
03
Conditions
Huntington disease (HD)
Beyond the preview
Go deeper on NL-OMON61722.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61722.